Dietary supplements can aid the management of psoriasis, yet effect estimates across the available evidence base remain inconsistent, according to findings reported by HCPLive.

That single two-part message — supplements help, but the size of the help varies — is the most clinically useful framing for dermatologists counseling patients who ask about nutraceutical adjuncts alongside prescription therapy.

What does the headline actually say?

The takeaway is not that supplements work or do not work. It is that the supplement literature for psoriasis produces a positive directional signal with a wide and unstable confidence interval around the effect size. In a treatment era where IL-17, IL-23 and TNF inhibitors routinely deliver PASI 90 and PASI 100 responses in registrational cohorts, the supplement signal sits at a different magnitude entirely.

That distinction matters at the clinic door. A patient who reads that supplements aid psoriasis treatment may infer equivalence with biologic-class outcomes. The variable effect-size estimate tells a more nuanced story.

Why do effect estimates vary?

Heterogeneity in supplement evidence typically arises from three recurring design problems.

• Endpoints are inconsistent. Trials use different PASI thresholds, different absolute versus relative reduction cut-offs, and different patient-reported quality-of-life instruments, which prevents meaningful pooling of results.
• Comparator arms differ. Some studies placebo-control, others compare supplement-on-top-of-standard-care versus standard-care alone, and few include an active comparator such as a topical corticosteroid or conventional systemic drug.
• The supplements themselves are rarely standardized across studies. Bioavailability, dose, and formulation change from trial to trial, and dose-ranging studies are uncommon, so the minimum effective dose for most candidate supplements remains unknown.

What should dermatologists tell patients today?

Counsel patients that any expected benefit from dietary supplements is unlikely to match biologic-class responses, and that supplements should serve as adjuncts to guideline-directed therapy rather than as replacements. Ask what the patient already takes. Flag potential interactions with prescribed systemic agents such as methotrexate, cyclosporine or acitretin, where high-dose folate, antioxidant stacking or hepatotoxic combinations may matter. Document the discussion and reassess outcomes at standard intervals.

A reasonable clinical posture: supplements are a low-risk adjunct option for patients with mild-to-moderate plaque disease who want a non-prescription component to their regimen, with the explicit expectation of modest effect size.

Where does the field go from here?

The variability in effect estimates makes a clear case for larger, adequately powered randomized trials with harmonized PASI endpoints, standardized supplement formulations, defined dose ranges, and head-to-head comparisons against active comparators. Until such trials land, supplements sit in the same evidence tier as many over-the-counter cosmeceuticals — a reasonable adjunct with modest expected benefit, awaiting the kind of phase 3 rigor the dermatology community now expects of prescription therapies.